Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 28 h ago

Cue Biopharma, Inc.: DRIEHAUS CAPITAL MANAGEMENT LLC amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Driehaus Capital Management LLC amended its Schedule 13G filing on Cue Biopharma, Inc., updating its beneficial ownership stake with the SEC under accession number 0000938206-26-000052. The filing signals a change in the institutional investor's position in the clinical-stage immunotherapy company. The amendment's details, including the exact percentage and share count held, were disclosed in the regulatory submission. Investors watch 13G amendments for signs of shifting institutional conviction in small-cap biotech names.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Driehaus Capital Management LLC, Cue Biopharma, Inc.